BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 29269277)

  • 1. Comprehensive Genomic Profiling of Malignant Effusions in Patients with Metastatic Lung Adenocarcinoma.
    Yang SR; Lin CY; Stehr H; Long SR; Kong CS; Berry GJ; Zehnder JL; Kunder CA
    J Mol Diagn; 2018 Mar; 20(2):184-194. PubMed ID: 29269277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accuracy of next-generation sequencing for the identification of clinically relevant variants in cytology smears in lung adenocarcinoma.
    Baum JE; Zhang P; Hoda RS; Geraghty B; Rennert H; Narula N; Fernandes HD
    Cancer Cytopathol; 2017 Jun; 125(6):398-406. PubMed ID: 28272845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liquid-based cytology specimens for next-generation sequencing in lung adenocarcinoma: challenges and evaluation of targeted therapy.
    Xiao X; Sun Z; Liang S; Li W; Guo H; Zhao H; Zhao L; Ma H; Sun Y; Wang C; Chang X; Zhang Z
    BMC Cancer; 2024 Jun; 24(1):749. PubMed ID: 38902688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.
    Drilon A; Wang L; Arcila ME; Balasubramanian S; Greenbowe JR; Ross JS; Stephens P; Lipson D; Miller VA; Kris MG; Ladanyi M; Rizvi NA
    Clin Cancer Res; 2015 Aug; 21(16):3631-9. PubMed ID: 25567908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer.
    Rozenblum AB; Ilouze M; Dudnik E; Dvir A; Soussan-Gutman L; Geva S; Peled N
    J Thorac Oncol; 2017 Feb; 12(2):258-268. PubMed ID: 27865871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FNA smears as a potential source of DNA for targeted next-generation sequencing of lung adenocarcinomas.
    Treece AL; Montgomery ND; Patel NM; Civalier CJ; Dodd LG; Gulley ML; Booker JK; Weck KE
    Cancer Cytopathol; 2016 Jun; 124(6):406-14. PubMed ID: 26882436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of EGFR gene mutation status from pleural effusions and other body fluid specimens in patients with lung adenocarcinoma.
    Zhang P; Wu X; Tang M; Nie X; Li L
    Thorac Cancer; 2019 Dec; 10(12):2218-2224. PubMed ID: 31602787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of reflex testing using focused next-generation sequencing for management of patients with advanced lung adenocarcinoma.
    Miller TE; Yang M; Bajor D; Friedman JD; Chang RYC; Dowlati A; Willis JE; Sadri N
    J Clin Pathol; 2018 Dec; 71(12):1108-1115. PubMed ID: 30228211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted deep sequencing of cell-free DNA in serous body cavity fluids with malignant, suspicious, and benign cytology.
    Yang SR; Mooney KL; Libiran P; Jones CD; Joshi R; Lau HD; Stehr H; Berry GJ; Zehnder JL; Long SR; Kong CS; Kunder CA
    Cancer Cytopathol; 2020 Jan; 128(1):43-56. PubMed ID: 31751001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequently used quantitative polymerase chain reaction-based methods overlook potential clinically relevant genetic alterations in epidermal growth factor receptor compared with next-generation sequencing: a retrospective clinical comparison of 1839 lung adenocarcinomas.
    Tønnesen E; Lade-Keller J; Stougaard M
    Hum Pathol; 2021 Sep; 115():67-75. PubMed ID: 34153308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted next-generation sequencing using fine-needle aspirates from adenocarcinomas of the lung.
    Karnes HE; Duncavage EJ; Bernadt CT
    Cancer Cytopathol; 2014 Feb; 122(2):104-13. PubMed ID: 24227699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subjecting appropriate lung adenocarcinoma samples to next-generation sequencing-based molecular testing: challenges and possible solutions.
    Li W; Qiu T; Ling Y; Gao S; Ying J
    Mol Oncol; 2018 May; 12(5):677-689. PubMed ID: 29518290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of next generation sequencing, SNaPshot assay and real-time polymerase chain reaction for lung adenocarcinoma EGFR mutation assessment.
    Cernomaz AT; Macovei II; Pavel I; Grigoriu C; Marinca M; Baty F; Peter S; Zonda R; Brutsche M; Grigoriu B
    BMC Pulm Med; 2016 May; 16(1):88. PubMed ID: 27215400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
    Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
    Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world utility of next-generation sequencing for targeted gene analysis and its application to treatment in lung adenocarcinoma.
    Kim JH; Yoon S; Lee DH; Jang SJ; Chun SM; Kim SW
    Cancer Med; 2021 May; 10(10):3197-3204. PubMed ID: 33960703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next-generation sequencing analysis of lung and colon carcinomas reveals a variety of genetic alterations.
    Chevrier S; Arnould L; Ghiringhelli F; Coudert B; Fumoleau P; Boidot R
    Int J Oncol; 2014 Sep; 45(3):1167-74. PubMed ID: 24990411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of solid tissue sequencing and liquid biopsy accuracy in identification of clinically relevant gene mutations and rearrangements in lung adenocarcinomas.
    Lin LH; Allison DHR; Feng Y; Jour G; Park K; Zhou F; Moreira AL; Shen G; Feng X; Sabari J; Velcheti V; Snuderl M; Cotzia P
    Mod Pathol; 2021 Dec; 34(12):2168-2174. PubMed ID: 34362997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted sequencing and intracranial outcomes of patients with lung adenocarcinoma brain metastases treated with radiotherapy.
    Press RH; Zhang C; Cassidy RJ; Ferris MJ; Zhong J; Steuer CE; Pillai RN; Owonikoko TK; Kahn S; Ramalingam SS; Patel PR; Curran WJ; Shu HG; Sica GL; Higgins KA
    Cancer; 2018 Sep; 124(17):3586-3595. PubMed ID: 30120912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective assessment of egfr mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing.
    Buttitta F; Felicioni L; Del Grammastro M; Filice G; Di Lorito A; Malatesta S; Viola P; Centi I; D'Antuono T; Zappacosta R; Rosini S; Cuccurullo F; Marchetti A
    Clin Cancer Res; 2013 Feb; 19(3):691-8. PubMed ID: 23243218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.